Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2011

WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng

  • WuXi Pharmaceuticals has bought two related Shanghai-based contract clinical research development services, MedKey Med-Tech Development and Jiecheng Med-Tech Development. Founded in 2006, the two acquired firms provide services spanning regulatory affairs, Phase I–IV clinical trials management, and clinical trial site management, throughout most of China.

    “This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers’ growing clinical development needs in the fast-growing Chinese healthcare market,” comments Ge Li, Ph.D., chairman and CEO.

    WuXi is a pharma, biotech, and medical device R&D outsourcing specialist with operations in China and the U.S. Just 10 days ago it reported acquiring antibody and peptide reagents firm Abgent, including the latter’s facilities in China and San Diego.  

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »